Pre-eclampsia is a syndrome characterized by inadequate placentation, which is due to deficient trophoblastic invasion of the uterine spiral arteries. This deficiency can lead to placental hypoxia, secretion of proinflammatory cytokines, and release of angiogenic and antiangiogenic factors. Hypoxic conditions in the placenta can promote oxidative stress and the production of angiogenic factors that are antagonized by soluble receptors, which are also elevated in this syndrome. In addition to these factors, the development of hypertension in women with preeclampsia may be associated with the renin-angiotensin system and endothelial dysfunction. The presence of antiangiotensin II type 1 receptor autoantibodies is relevant in pre-eclampsia because it has been related to the secretion of antiangiogenic factors through cytokine pathways, indicating that autoimmune mechanisms may participate in the pathophysiology of this syndrome.
INTRODUCTION
Approximately 4%-6% of all pregnancies are affected by pre-eclampsia [1] , a pregnancy disorder characterized by hypertension and proteinuria after the 20th week of gestation [2] . In the first weeks of pregnancy, normal spiral artery remodeling is achieved by the migration of differentiated cytotrophoblasts into the uterine spiral arteries [3] . However, in pre-eclampsia, vascular remodeling of the spiral arteries that provide blood to the intervillous spaces may not be achieved, promoting diminished placental perfusion [4] , and may be related to high uteroplacental intravascular resistance present in this syndrome [5] .
The precise cause of pre-eclampsia has not been clearly defined [6] . Researchers have suggested that an association exists among impaired angiogenesis, changes in local oxygen tension [7] , and immunological alterations in the early placental microenvironment [8] . However, immunological factors may not only participate in the origins of pre-eclampsia. The immune system can later contribute to the pathophysiology, and one mechanism may be through the development of autoantibodies that activate the renin-angiotensin system (RAS) [9] and modulate the secretion of antiangiogenic factors.
CONSEQUENCES OF A PERSISTENT HYPOXIC PLACENTAL MICROENVIRONMENT IN PRE-ECLAMPSIA
The early stages of placental development take place in an environment that is hypoxic with respect to the uterus because blood flow to the intervillous space does not begin until gestation weeks 10-12 [10] . The physiological hypoxia observed in the first weeks of normal gestation promotes trophoblast proliferation rather than differentiation [11] . However, in pre-eclampsia, the persistence of low oxygen tension and the presence of hypoxia-inducible factor-1 alpha (HIF-1a) foster a proliferative noninvasive phenotype of the trophoblast [12] . Placental overexpression of HIF-1a is due to various factors including local hypoxia and altered oxygendependent degradation of the HIF-1a protein [13] . HIF-1a promotes the expression of transforming growth factor-b3 (TGF-b3), an inhibitor of extravillous trophoblast differentiation [14, 15] . Both HIF-1a and TGF-b3 are overexpressed in the pre-eclamptic placenta [15] , and they are considered indicative of persistent hypoxic conditions in the human placenta [15] .
ANGIOGENIC FACTORS ASSOCIATED WITH THE PATHOPHYSIOLOGY OF PRE-ECLAMPSIA
Several factors participate in angiogenesis in pregnancy and are involved in the mechanisms that control maternal cardiovascular adjustment to pregnancy, including vascular endothelial growth factor (VEGF) [16] and placental growth factor (PlGF). VEGF transcription is strongly induced under hypoxic conditions via HIF-1a [17] . HIF-1a increases VEGF and endoglin (ENG) expression through the phosphatidylinositol-3-kinase, Akt, mammalian target of rapamycin (PI3K-Akt-mTOR) and extracellular signal-regulated kinase (ERK) pathways, as shown in a trophoblast cell line [18] . The hypoxia-dependent regulation of PlGF in trophoblast-derived cells involves metal-responsive transcription factor-1 (MTF-1) [19, 20] .
In pre-eclampsia, an imbalance between pro-and antiangiogenic factors has been observed. Proangiogenic factors include VEGF and PlGF, and antiangiogenic factors include the soluble ENG (sENG) [21] and the soluble VEGF receptor 1 (sVEGF-R1) [22, 23] and its generic splice variant, known as the soluble form of fms-like tyrosine kinase 1 (sFlt1) [23] . ENG is a coreceptor for TGF-b that is expressed on cytotrophoblasts during the first trimester and is promoted by TGF-b1 and TGF-b3. The presence of transmembrane ENG is related to a decrease in invasive functions, and sENG is increased in pre-eclamptic patients [24] . In contrast, sFlt1 is a powerful inhibitor of VEGF and PlGF, because it binds to these factors in the maternal circulation and blocks their angiogenic effects [25] . sFlt1 levels are relatively low early in normal pregnancy [26] . However, the presence of low oxygen conditions promotes the release of sENG and sFlt1 from the placenta [27, 28] . Consequently, high levels of sFlt1 and low levels of PlGF predict the subsequent development of preeclampsia, and their altered levels can be detected 5 weeks before the onset of this syndrome [29] . Furthermore, concurrent measurements of sFlt1, PlGF, and uterine perfusion in pregnant women can help predict early onset pre-eclampsia with 83% sensitivity and 96% specificity [30] . Endothelin-1 (ET-1) is also increased in women with pre-eclampsia and is correlated with sFlt1 and sENG levels in these patients [31] .
sFlt1, which is produced by the hypoxic villous trophoblast, participates in the clearing of free maternal VEGF [32] . Two isoforms of sVEGF-R1 have been described: sFlt1, which is generic, and sFlt1-14, which is human specific [23] . sFlt1-14, also known as sFlt1-e15a, is a C-terminal variant isoform of sFlt1 and is the most common VEGF inhibitor produced by the human placenta in pre-eclampsia [33] . In the presence of hypoxia, sFlt1-14 accumulates in the maternal circulation, neutralizing VEGF in distant organs and extending the impact of pre-eclampsia [34] .
It is unknown which factors trigger the early increase in antiangiogenic factors in pregnancies with future disease, but it has been suggested that hypoxia may modulate the production and/or release of sFlt1 [35] and VEGF by villous trophoblast [32] . In contrast, the concentration of sENG is not directly regulated by hypoxia [32] . Thus, other mechanisms are involved in the increased vascular resistance in pre-eclampsia. It has been suggested that decreased vascular relaxation mediators, such as nitric oxide [36] and prostacyclins [37] , and increases in mechanisms that promote vascular smooth muscle contraction may also be important causes [38] .
Interestingly, increased placental production of sFlt1 may also be related to proteinuria and glomerular endotheliosis in patients with pre-eclampsia, which may influence the severity of this condition [25] . Sugimoto et al. [39] demonstrated in mice that VEGF plays an important role in preserving homeostasis of the kidney glomerulus and that sFlt1 or antibodies against VEGF may cause proteinuria by reducing the expression of nephrin, a protein of the glomerular slit diaphragm that constitutes a barrier to large serum proteins. Blocking VEGF may accelerate kidney disease in preeclampsia because this molecule maintains the integrity of the glomerular endothelium [40] . In addition, sENG along with sFlt1 may participate in the pathophysiology of pre-eclampsia by elevating blood pressure [41] . In vitro studies have shown that sENG can be released by endothelial cells and promote endothelial dysfunction present in pre-eclampsia [42] . Figure 1 shows the relationships between hypoxia and the production of pro-and antiangiogenic factors in the development of endothelial dysfunction and hypertension in preeclampsia.
RENIN-ANGIOTENSIN SYSTEM IN PRE-ECLAMPSIA
Women with normal pregnancies have a twofold increase in plasma concentration of angiotensin II (AGT II); however, women remain normotensive because of resistance to the vasopressor effects of AGT II. The consequences of elevated AGT II in normal pregnancy are still unknown, and the participation of RAS in pre-eclampsia is also not fully understood [43] . A complete RAS has been described in both placental and decidual tissues in normal human pregnancies [44] , and components of the RAS may be involved in the pathophysiology of pre-eclampsia [45] . For example, polymorphisms in alleles of AGT are associated with essential hypertension and pre-eclampsia [46] . In addition, the decidual expression of AT1 receptor (AT1-R), the gene encoding the angiotensin II type 1 receptor, is higher in pre-eclampsia than in normal pregnancies [45] , and chorionic villi also show upregulation of AT1-R mRNA in this syndrome. Likewise, the AGT II concentration in the chorionic villi is increased in preeclampsia and may promote vasoconstriction and blood flow reduction in the uteroplacental unit [43] . Furthermore, factors derived from the pre-eclamptic placenta may trigger endothelial cell AGT II overproduction in vitro [47] .
PARTICIPATION OF THE IMMUNE SYSTEM IN RAS ACTIVATION IN PRE-ECLAMPSIA
The immune system can participate in the activation of RAS in pre-eclampsia through the development of stimulatory AGT II type 1 receptor autoantibodies (AT1-AAs) of the immunoglobulin G (IgG) isotype [9] . Approximately 70%-95% of preeclamptic patients have elevated levels of AT1-AAs [48, 49] . Participation of AT1-AAs in the development of pre-eclampsia was demonstrated by injecting AT1-AAs from pregnant women into pregnant mice. The injected human AT1-AAs were able to induce key features of pre-eclampsia, including hypertension, proteinuria, placental abnormalities, and the classical renal lesion of this syndrome glomerular endotheliosis [50] . The ability of AT1-AAs to induce hypertension in FIG. 1. Persistent placental hypoxia, which is present in the preeclamptic placenta, promotes release of HIF-1a. HIF-a favors the expression of TGF-b3, which can lead to decreased trophoblast differentiation and decreased invasion at the beginning of pregnancy, thus contributing to persistent hypoxic conditions in the placenta later in pregnancy. VEGF and PlGF are induced under hypoxic conditions and are inhibited by sFlt1. sFlt1-14 is the most common human VEGF inhibitor. TGF-b3 also promotes the production of sENG. Together, sENG and the blockade of VEGF are involved in endothelial dysfunction. Blue arrows indicate progressive events and stimulatory or promoting factors; red lines indicate inhibitory factors.
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Although these antibodies do not bind the same epitope as those found in pre-eclamptic patients, they are able to induce graft rejection and malignant hypertension [51] . AT1-AAs signal human trophoblast and vascular cells [52] , and the binding of AT1-AAs to AT1-R induces sFlt1 and sENG production by human villous explants through tumor necrosis factor (TNF)-a pathways [53, 54] . AT1-AA ligation increases TNF-a signaling, which promotes interleukin (IL)-6 production that induces ET-1 production by human placental villous explants [55] . TNF-a is also increased in pre-eclampsia due to the presence of placental ischemia [56, 57] , and it stimulates placental production of sENG and sFlt1 [58] . AT1-AAs can also promote vasoconstriction through TNF-a-independent pathways. For example, AT1-AA binding to the AT1 receptor on vascular smooth muscle cells induces vasoconstriction [59] , and AT1-AAs can mediate hypertension because they stimulate placental oxidative stress [60, 61] . High levels of AT1-AAs correlate with the severity of the disease because they are associated with the presence of hypertension, proteinuria, and sFlt1 [49] . Patients with pre-eclampsia and AT1-AAs have higher sFlt1 levels [53] , lower VEGF levels, and greater insulin resistance than women without AT1-AAs [62] . Similar to sFlt1 and insulin resistance, AT1-AAs do not disappear completely after childbirth [62] . Although AT1-AAs antibodies are present in 70% of women with pre-eclampsia, these antibodies are not exclusively of this syndrome; they have also been found in 20% of women with gestational hypertension, and they contribute to hypertension by activating AT1 receptors [48] . Lack of proteinuria in women with AT1-AAs and gestational hypertension has been attributed to lower levels of sFlt1 [49] . Because AT1-AAs are able to cross the placental barrier [45] , these antibodies may also contribute to intrauterine growth restriction indirectly, by inducing apoptosis in the placenta, and directly, by activating AT1-R on the surface of fetal organs [63] . Adequate and rapid bioassays to detect agonistic AT1-AAs for clinical use are not yet available. However, Siddiqui et al. [49] have recently developed a sensitive luciferase bioassay for the detection of AT1-AAs.
These data highlight the participation of autoantibodies in the pathophysiology of pre-eclampsia [9] , not only demonstrating the importance of B cells in this disease but also raising the hope of a possible therapeutic target by antagonizing the AT1 signaling pathway.
AT1-AAs AND AUTOREACTIVE B LYMPHOCYTES IN PRE-ECLAMPSIA
Little is known regarding the origin of autoreactive lymphocytes in pre-eclampsia, especially those B cells that recognize and produce the AT1 antibodies that participate in its pathophysiology.
Due to somatic recombination of the V,D and J genes of the B cell receptor (BCR), a diverse repertoire of BCRs and antibodies can be present in an individual [64] . However, this can also lead to the development of B cells expressing autoreactive BCRs, which must be eliminated by negative selection mechanisms [65] . Autoimmunity can arise when the mechanisms involved in tolerance to self-antigens do not eliminate autoreactive B cells [66] . B cell tolerance and autoantibody regulation require central and peripheral mechanisms in which receptor editing, anergy, and deletion of autoreactive B cells play an important role [67] . However, some autoreactive B cells may persist and may become anergic, and their activation requires costimulation by T cells [68] .
Autoreactive B cells may also be activated in a T-cellindependent manner by Toll-like receptor (TLR) engagement [69] . Further research is needed concerning the triggers that may disrupt immune tolerance in pregnant women who develop AT1-AAs in pre-eclampsia. Several mechanisms may be involved in the generation of autoreactive B cells and autoantibodies in pre-eclampsia, including participation of circulating free fetal RNA in the plasma of pregnant women [70] , an inflammatory cytokine pathway (via TNF-a or IL-6 cytokines) [71] , the presence of damage-associated molecular patterns (DAMPs), which bind TLRs [72] , and altered regulation of CD19 þ CD5 þ B cells [73] .
Circulating Free Fetal Nucleotides
Fetal nucleic acids are present in the serum of women who develop pre-eclampsia, and circulating fetal DNA may be five times higher in pre-eclamptic women than in those with normal pregnancies [74] . Considering that RNA may be able to enter cells as an undegraded molecule [75] , it has been hypothesized that fetal RNA may be able to transfect maternal cells and induce the expression of fetal epitopes, promoting the loss of immune tolerance to certain antigens in the mother [70] . Furthermore, DNA and DNA-associated antigens may activate autoreactive B cells by binding the BCR and the TLR9 [76] . This two-receptor paradigm also applies when RNA and RNAassociated autoantigens bind the BCR and TLR7, promoting the activation of autoreactive B cells [77] . These events represent a link between the adaptive and innate immune system in the development of autoantibodies [76] .
Inflammatory Cytokine Pathway
Inflammatory cytokines such as IL-6, TNF-a, and IL-16 are increased in women with pre-eclampsia [78, 79] , and some of these cytokines have been associated with autoimmunity. IL-6 has been related to hyperactivation of B and T cells, generation of pathogenic autoantibodies in mice [80] , and activation of autoimmune T cells in murine myocarditis [81] . Elevated levels of IL-6 have also been identified in patients with lupus [82] , and anti-IL-6 monoclonal antibodies can suppress autoantibody responses, as shown in a mouse model of systemic lupus erythematosus (SLE) [83] . On the other hand, TNF-a has a dual action in matters of autoimmunity, which can depend on the activation of different TNF receptors [84] . TNF-a may promote autoimmunity by inhibiting the suppressive functions of CD4 þ CD25 þ T regulatory cells [85] , and it participates in autoimmune diseases via activation of TNF receptor 1 [86] . However, it may also be considered potentially immunoregulatory when signaling through TNF receptor 2, because it can decrease IL-12 [87] and IL-23 production in antigen-presenting cells [88] .
The persistence of inflammatory cytokines in pregnant women may be perpetuated by placental hypoxic conditions [78] , circulating syncytiotrophoblast microparticles (STBMs) [89] , or TNF-a-producing AT1-R-positive lymphocytes [90] . STBMs that are shed from the placenta cause endothelial dysfunction that leads to leukocyte activation and release of proinflammatory cytokines [91] . Furthermore, binding of STBMs stimulates the release of inflammatory cytokines in monocytes, contributing to the systemic inflammatory response in pre-eclampsia [89] . T lymphocytes may also contribute to the presence of proinflammatory cytokines in pre-eclampsia [90] because these cells have an endogenous angiotensin system, produce AGT II and have AT1-R [92] . Because the secretion of AGT II promotes the release of TNF-a by T ANGIOGENIC FACTORS AND AT1-AAS IN PREECLAMPSIA lymphocytes, these cells may have a role in both genesis of hypertension and production of proinflammatory cytokines [90] . Altogether, placental ischemia and high levels of TNF-a may stimulate the presence of AT1-AAs in pregnant rats [93] .
Toll-Like Receptor Engagement
TLR activation represents a T-cell-independent mechanism by which B cells can be activated [76] . The presence of DAMPs, such as the high mobility group box-1 protein (HMGB1) [94] and S100 [95] in pre-eclampsia, could participate in the development of autoantibodies in preeclamptic patients, as it occurs in other autoimmune diseases like SLE and arthritis, where DAMPs may promote autoantibody production through TLR-mediated inflammation [72] . HMGB1 and apoptotic cell-derived nucleosomes may contribute to breaking immune tolerance in SLE because of their proinflammatory effects in dendritic cells and macrophages [96] . In addition, contents from apoptotic cells, like free oligonucleosomes, can act as nonspecific adjuvants of B lymphocyte stimulation [97] . Considering that pre-eclamptic patients have higher levels of circulating fetal DNA [74] and increased placental apoptosis [98] , the binding of DNA or apoptotic material to HMGB1 proteins, and the subsequent activation of TLRs in antigen presenting cells, may be a proinflammatory mechanism promoting the development of autoantibodies in pre-eclampsia.
Recently, a CD19 þ CD5 þ B cell population has been identified in the placenta of pre-eclamptic patients, which is able to produce AT1-AAs [99] . Human CD19 þ CD5 þ B cells share phenotypic properties with murine B-1a lymphocytes [73] . B-1a cells have been involved in the generation of autoantibodies in mice and depend on CD19 signaling for their development [100] . In humans, CD5 þ B cells are able to activate somatic hypermutation mechanisms and thus may accumulate mutations in the variable regions of the BCR [101] , which can lead to the generation of autoreactive B cells [102] . Human peripheral blood and spleen CD5 þ B cells can produce polyspecific autoreactive antibodies [103] , and autoantibodyproducing CD19
þ CD5 þ cells may be present in Sjögren syndrome [104] and other autoimmune diseases [105] . Identification of CD19 þ CD5 þ B cells that are able to produce AT1-AAs [99] represents an important leap in the understanding of the development of autoantibodies in pre-eclampsia. However, mechanisms promoting their presence have not yet been described and may involve some of the aforementioned pathways. Figure 2 shows the relationships among hypoxia, STBMs, apoptotic cell content, and inflammatory cytokines. Development of AT1-AAs and the effects of these autoantibodies are also illustrated.
CONCLUSIONS Persistent hypoxia at the placental level is an important factor that contributes to the pathophysiology of pre-eclampsia. Hypoxic conditions can promote the presence of proangiogenic factors such as VEGF and PlGF as well as antiangiogenic factors such as sFlt1 and sFlt1-14 that antagonize the effect of proangiogenic molecules. In addition, high levels of AGT II in the chorionic villi contribute to the hypertension in this disorder. The mechanisms that lead to this particular increase in AGT II have not been fully elucidated. The presence of autoantibodies against AT1-R may be a linking factor between antiangiogenic and immunological factors in pre-eclampsia because these antibodies promote the release of TNF-a and IL-6 and the subsequent production of sFlt1, sENG, and ET-1 via AT1-R activation.
Because the origin and pathophysiology of pre-eclampsia have been related to immune system dysregulation and to the presence of autoantibodies against AT1, this disease can include autoimmune characteristics. However, the mechanisms that promote the presence of autoreactive B lymphocytes against angiotensin receptors in pre-eclampsia are still unknown. The finding of AT1-AAs in women with gestational hypertension may provide a new perspective regarding the mechanisms of action of these autoantibodies, and the factors promoting their presence in gestational hypertension should be explored as well.
The imbalance between angiogenic factors, soluble receptors that block their action, and the presence of elevated levels of AGT II and AT1-AAs may increase the impact of preeclampsia but may also suggest potential indicators for early diagnosis and therapeutic targets for this syndrome. Autoreactive B lymphocytes may be generated in the presence of increased fetal RNA in the maternal plasma by transfection of maternal cells by fetal RNA or as a result of the persistence of inflammatory cytokines. Continued expression of cytokines is promoted by hypoxia, STBMs, and DAMPs. RAS þ T lymphocytes and release of apoptotic cell content may have inflammatory actions as well. Binding of AT1-AAs to AT1-R leads to the production of sFlt1 and sENG in a TNF-a-dependent manner and the release of ET-1 via IL-6 signaling. TNF-a production can also be a consequence of placental ischemia, resulting in increased sENG and sFlt1 levels. AT1-AAs also promote placental oxidative stress, participating in the induction of hypertension. Blue arrows describe progressive events and stimulatory or promoting factors. The red question marks indicate possible, unconfirmed mechanisms. Ovals indicate cytokine-mediated pathways.
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